CASE No COMP/M.3099 : Areva / Urenco / ETC JV
- Summary of the facts.
- Arguments of the European Commission.
- Reasons for the decision.
- The nature of the proposed remedies.
- Advantages and disadvantages of what is proposed by the Commission.
The European Commission is vested with a responsibility of assessing compatibility between the markets and the various merging firms. In its decision of 6th October 2004, the Commission has assessed the compatibility with the common market of the concentration of two firms from the nuclear industry sector, following the procedure laid down in the merger regulation. This concentration was proposed by the French company, Areva and was aimed at the creation of a joint venture, by a common control of ETC (Enrichment Technology Company Limited), a British undertaking which used to be wholly controlled by the British holding, Urenco Limited. In this case, the Commission assessed the potential effects of this concentration on competition, since it raises serious doubts about the compatibility of this operation with the common market. In order to comment on this case, we will summarize the facts at stake, examine the arguments of the commission and arrive at the conclusion. We will also have a closer look at the remedies proposed before weighing the advantages and drawbacks of the Commission's proposition.